Findings based on primary composite outcome of IBD-related hospitalization or surgery with 394 days of median follow-up
Adults With IBD Show Antibody Response to mRNA COVID-19 Vaccine
After mRNA COVID-19 vaccination, 99 percent of patients with IBD had detectable antibodies regardless of immunocompromising therapies
Clinically Active IBD Linked to Adverse COVID-19 Outcomes
Measure indicating greater activity of IBD independently linked to ICU/ventilation/death and hospitalization among patients 50 years or younger
Risk for VTE Up for IBD Patients Infected With SARS-CoV-2
Odds of VTE increased 8.15-fold according to models adjusting for recent hospitalization and steroid exposure
Risk for Adverse Events Not Increased After COVID-19 Vaccine in IBD
Frequency of adverse events was higher for those younger than 50 years, individuals with prior COVID-19 history
Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine
Antibody concentrations lower in infliximab-treated individuals with IBD receiving single dose of BNT162b2 or ChAdOx1 nCoV-19 vaccine
Response to COVID-19 Vaccine Positive in Patients With IBD
Antibody response in IBD patients, including those receiving biologic therapy at the time of vaccination, similar to that of controls without IBD
Infliximab May Impede Serologic Response to SARS-CoV-2
Concomitant immunomodulator use further blunted antibody responses to SARS-CoV-2 among infliximab-treated IBD patients